People · Operator
Named in public records as an officer, director or promoter · active 2020–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. | — | Pharmaceuticals | Series D+ | $118.0M | $2.4B | 2022 |
| Exalys Therapeutics, Inc. | — | Pharmaceuticals | Series A | $4.0M | $123.9M | 2020 |
Brian Taylor Slingsby at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Brian Taylor Slingsby on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Srinivas Akkaraju | 1 | 10 |
| Derek DiRocco | 1 | 7 |
| Dennis Podlesak | 1 | 6 |
| Lynne Rollins | 1 | 5 |
| Rick Orr | 1 | 5 |
| Eckard Weber, M.D. | 1 | 5 |
| NICOLE VITULLO | 1 | 4 |
| Michael Sanders | 1 | 3 |
| Adam Levy | 1 | 3 |
| Olivier Litzka | 1 | 2 |
| Alexander Asam | 1 | 2 |
| Jon Congleton | 1 | 1 |
| Takeshi Takahashi | 1 | 1 |
| Takeshi Taylor Takahashi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.